Overview CD40 Protein Structure and Expression Functions Mechanism of Action Role in Cancer CD40 Pathway as Therapeutic Target Pipeline Therapeutics (Active Products) Comparative Analysis Mid-Stage Products (Phase II) Comparative Analysis APX005M: Apexigen Product Description Research and Development Product Development Activity (The list continues) Early Stage Products (Phase I) Comparative Analysis Pre-Clinical Stage Products Comparative Analysis Therapeutic Assessment Assessment by Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant and Discontinued Products Comparative Analysis Appendix

Table 1: Total Products for CD40 agonist Table 2: Mid Stage Products (Phase II) Table 3: Early Stage Products (Phase I) Table 4: Pre-Clinical Stage Products Table 5: Assessment by Route of Administration for CD40 agonist Table 6: Assessment by Stage and Route of Administration Table 7: Assessment by Molecule Type Table 8: Assessment by Stage and Molecule Type Table 9: Dormant and Discontinued Products Figure 1: Functional Consequences Of CD40 Signaling Figure 2: TRAF And Jak3 Dependent CD40 Signalling Pathway Figure 3: Role Of CD40 In Immune Response Against Cancer Figure 4: Total Products for CD40 agonist Figure 5: Mid Stage Products (Phase II) Figure 6: Early Stage Products (Phase I) Figure 7: Pre-Clinical Stage Products Figure 8: Product Type Figure 9: Assessment by Route of Administration Figure 10: Assessment by Stage and Route of Administration Figure 11: Assessment by Molecule Type Figure 12: Assessment by Stage and Molecule Type Figure 13: Dormant and Discontinued Products

Apexigen Cellular Biomedicine Group Abbvie Janssen Biotech Memgen Denceptor Seattle Genetics Roche Celldex Therapeutics AbbVie Apogenix ImmuNext University of Southampton Seattle Genetics